Argitalpenak (39) MONICA CABRERO CALVO argitalpenak

2024

  1. Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial

    Bone Marrow Transplantation

  2. Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia

    Bone Marrow Transplantation

  3. Treatment of post-allogeneic hematopoietic stem cell transplant cytopenias with sequential doses of multipotent mesenchymal stromal/stem cells

    Cytotherapy

2022

  1. ABCL-297 Hemophagocytic Lymphohistiocytosis Singularity: A Multicenter Retrospective Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S369-S370

  2. Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups

    Cancers, Vol. 14, Núm. 22

  3. CT-169 Cytokine Release Syndrome After Peripheral Blood Haploidentical Stem Cell Transplantation With Post-Transplant Cyclophosphamide: Time of Onset Matters

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S437-S438

  4. CT-275 Incidence and Characteristics of Chronic GVHD in Haploidentical Stem-Cell Transplantation With Post-Transplantation Cyclophosfamide: Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S440-S441

  5. MM-198 Anti-BCMA Therapy in Multiple Myeloma: A Single-Center Experience

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S413

2021

  1. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study

    Bone Marrow Transplantation, Vol. 56, Núm. 8, pp. 1919-1928

  2. Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 10, pp. e801-e809

  3. Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors

    Bone Marrow Transplantation

2020

  1. Measures to Maintain a SARS-CoV-2 Negative Inpatient Hematological Unit in the Midst of the COVID-19 Pandemic

    Frontiers in Medicine, Vol. 7

2019

  1. Anemia hemolítica

    Manual terapéutico (Ediciones Universidad de Salamanca), pp. 389-393

  2. Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation

    Annals of Hematology, Vol. 98, Núm. 9, pp. 2151-2162

  3. Drug-induced thrombotic microangiopathy during maintenance treatment in a patient with multiple myeloma

    HemaSphere, Vol. 3, Núm. 3

  4. Púrpura trombótica trombocitopénica (PTT) / síndrome hemolítico urémico atípico (SHUA)

    Manual terapéutico (Ediciones Universidad de Salamanca), pp. 394-396

  5. Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation

    Bone Marrow Transplantation

2017

  1. 18F-FDG PET/CT in the clinical management of patients with lymphoma

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 36, Núm. 5, pp. 312-321

  2. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

    American Journal of Hematology, Vol. 92, Núm. 4, pp. 351-358

  3. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

    Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 1, pp. 53-59